OBJECTIVE: To purify low density lipoprotein(LDL)from human plasma and label LDL used99m Technetium (99m Tc) for the advanced research of LDL as a carrier targeting antitumor drug to cancer cells.METHODS: A flotated ultracentrifugation of KBr density gradient solution was used to isolate LDL from human plasma.LDL was labeled with 99m Tc using sodium dithionite as a reducing agent of 99m pertechnetate. RESULTS:Ultracentrifugation was performed at 40 000 r·min-1 in a ultracentrifuge for 24 h at 4℃.The ratio of KBr density solutions was 1.5:2:3:5, each density was 1.006,1.019,1.063 and 1.210(serum contained KBr) respectively. The electrophoretic pure LDL was prepared by ultracentrifugation mentioned above. LDL was labeled with 99m Tc. The labeling effectivity was about 39.73%.CONCLUSION: The KBr density gradient ultracentrifugation could be used to isolate and obtain pure LDL from human plasma. And LDL could be labeled with 99m Tc for further research.
Key words
low density lipoprotein /
purification /
radiolabeled /
targeting carrier
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Jackson RL, Morrisett JD, Gotto AM, et al .Lipoproteinstructure and metabolism. Physiol Rev, 1976;56:259.
2 Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. J Biol Chem, 1974;249:5153.
3 Vitols S, Gahrton G, Ost A, et al. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood, 1984;63:1186.
4 Rudling MJ, Angelin B, Peterson, et al .Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res,1990;50:483.
5 Lundberg B. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. CattcerRes, 1987;47:4105.
6 Lestavel-Delattre S, Martin-Nisard F, Clavey V, et al. Lowdensity lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res,1992;52:3629.
7 Samadi-Baboli G, Favre G, Canal V, et al. Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer, 1993;68:319.
8 江志强，马远鸣.低密度脂蛋白及其作为新型药物载体的研究进展.中国生化药物杂志,1996;17(4):180.
9 Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. Adv Lzp Res, 1968;6:1.
10 Lees RS, Garabedian HD, Lees RS, et al:Technetium-99m low density lipoproteins: Preparation and biodis-tribution. J Nucl Med, 1985;26:1056.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
